THC

THC is the primary psychoactive cannabinoid in Cannabis sativa, functioning as a partial agonist at CB1 and CB2 receptors of the endocannabinoid system to modulate pain signaling, nausea, appetite, and neuroprotection. FDA-approved synthetic THC formulations (dronabinol) demonstrate clinically significant antiemetic efficacy in chemotherapy-induced nausea and vomiting, and cannabinoid-based medicines containing THC have shown statistically significant reductions in neuropathic pain in multiple controlled trials.

Origin & History

Delta-9-tetrahydrocannabinol (THC) is a phytocannabinoid biosynthesized in the trichomes of Cannabis sativa L. and Cannabis indica plants, originating from Central Asia and the Indian subcontinent where cannabis has been cultivated for thousands of years. THC accumulates predominantly in the unfertilized female flower heads (sinsemilla), with modern high-potency cultivars producing concentrations exceeding 30% THC by dry weight through selective breeding. The compound is biosynthesized from the precursor THCA (delta-9-tetrahydrocannabinolic acid) via enzymatic activity in glandular trichomes, and converts to active THC through decarboxylation induced by heat or aging.

Historical & Cultural Context

Cannabis has been used medicinally for at least 5,000 years, with the earliest documented use in the Chinese pharmacopeia Shennong Bencao Jing (circa 2700 BCE), which described cannabis preparations for pain, rheumatism, malaria, and constipation. In Ayurvedic medicine, cannabis preparations (known as bhang, charas, and ganja) were used for analgesic, hypnotic, and antispasmodic purposes, while Islamic physicians including Ibn Sina (Avicenna) documented its use for headaches and pain in the 11th century Canon of Medicine. Western medicinal use expanded in the 19th century following William Brooke O'Shaughnessy's 1839 clinical report introducing cannabis to European medicine for tetanus, rheumatism, and cholera, leading to widespread inclusion of cannabis tinctures in the US and UK pharmacopeias until prohibition in the 1930s. The isolation and structural elucidation of THC was achieved by Raphael Mechoulam and Yechiel Gaoni at the Weizmann Institute of Science, Israel, in 1964, marking the foundation of modern cannabinoid science.

Health Benefits

- **Analgesic (Pain Relief)**: THC activates CB1 receptors in the dorsal horn of the spinal cord and periaqueductal gray matter, inhibiting the release of pro-nociceptive neurotransmitters; clinical trials in neuropathic and cancer-related pain have demonstrated significant pain score reductions compared to placebo.
- **Antiemetic Effect**: THC suppresses chemotherapy-induced nausea and vomiting through CB1 receptor agonism in the dorsal vagal complex and nucleus tractus solitarius; dronabinol (synthetic THC) is FDA-approved for this indication and has shown superiority over placebo in multiple controlled trials.
- **Appetite Stimulation**: THC activates hypothalamic CB1 receptors and modulates ghrelin signaling to increase appetite and caloric intake, a mechanism that underlies FDA-approved dronabinol use in HIV/AIDS-associated anorexia and cachexia.
- **Neuroprotection**: At concentrations of approximately 3 µM, THC has demonstrated protection against NMDA-induced apoptosis in neuronal cells by blocking reactive oxygen species (ROS) generation, suggesting potential utility in excitotoxic neurological conditions.
- **Anti-inflammatory Activity**: THC modulates CB2 receptors on immune cells to reduce pro-inflammatory cytokine release (TNF-α, IL-6) and may suppress microglial activation, contributing to its therapeutic relevance in inflammatory and autoimmune-associated pain states.
- **Intraocular Pressure Reduction**: THC has demonstrated acute reduction of intraocular pressure through cannabinoid receptor-mediated mechanisms, historically investigated as a potential adjunct in glaucoma management, though duration of effect limits clinical utility.
- **Anxiolytic and Sleep-Modulating Effects**: At low doses, THC may reduce anxiety and improve sleep onset through CB1 receptor modulation of the amygdala and hypothalamic-pituitary-adrenal axis, though higher doses can paradoxically induce anxiety and are dose-dependent.

How It Works

THC exerts its primary pharmacological effects as a partial agonist at CB1 receptors (predominantly in the central nervous system, including the basal ganglia, hippocampus, cerebellum, and dorsal horn) and CB2 receptors (predominantly on immune cells and peripheral tissues), both of which are G-protein-coupled receptors (Gi/Go) that inhibit adenylyl cyclase and reduce cAMP, modulate ion channels (inhibiting voltage-gated calcium channels and activating inwardly rectifying potassium channels), and decrease neurotransmitter release. THC's lipophilicity (logP ~7) enables rapid penetration of the blood-brain barrier and partitioning into lipid bilayers, explaining its extensive distribution into adipose tissue and prolonged terminal half-life of approximately 22 hours. At the cellular level, THC at 3 µM has been shown to block NMDA receptor-induced reactive oxygen species generation, providing neuroprotection against excitotoxic apoptosis, while at concentrations of 0.1–100 µM it increases insulin release and upregulates pancreatic transcription factor Pdx1 and glucose transporter Glut2 in vitro. THC is metabolized hepatically by CYP2C9 and CYP3A4 to its primary active metabolite 11-hydroxy-THC (11-OH-THC), which is subsequently oxidized to the inactive 11-nor-9-carboxy-THC (THC-COOH), the major urinary metabolite used in drug screening.

Scientific Research

The clinical evidence base for THC is moderate to strong for specific indications such as chemotherapy-induced nausea and vomiting (CINV) and neuropathic pain, supported by multiple randomized controlled trials and systematic reviews, while evidence for other applications remains preliminary or preclinical. FDA approval of dronabinol (synthetic THC) for CINV (1985) and AIDS-related anorexia (1992) reflects a regulatory evidence threshold met by multiple controlled trials, and nabiximols (THC:CBD oromucosal spray) has been approved in over 25 countries for multiple sclerosis-related spasticity based on phase III RCT data. A 2018 Cochrane review of cannabinoids for chronic neuropathic pain analyzed data from 16 RCTs and found a moderate-quality evidence base suggesting benefit over placebo, with number-needed-to-treat values of approximately 11 for 30% pain reduction. The in vitro data on insulin secretion, ROS modulation, and neuroprotection are promising but remain at the preclinical stage, and robust large-scale human trials for these mechanisms are lacking as of the current evidence landscape.

Clinical Summary

Dronabinol (synthetic delta-9-THC) has been evaluated in multiple RCTs for CINV, with early trials demonstrating response rates of 25–38% compared to 15% for placebo, though it has largely been superseded by 5-HT3 antagonists as first-line therapy. In chronic neuropathic pain, nabiximols (a standardized THC:CBD extract at approximately 2.7 mg THC per spray) demonstrated statistically significant reductions in pain NRS scores versus placebo in phase III trials, with effect sizes modest but clinically meaningful for treatment-refractory patients. For multiple sclerosis spasticity, a pivotal phase III trial (n=572) showed a statistically significant reduction in spasticity NRS scores with nabiximols versus placebo (p<0.0001), forming the basis for regulatory approval in the UK, Canada, and the EU. Overall, the clinical evidence supports THC-based medicines as third-line or adjunct options for neuropathic pain and spasticity, with highest confidence in the antiemetic indication due to longest evidence history.

Nutritional Profile

THC is a terpenophenolic compound (molecular formula C21H30O2, molecular weight 314.46 g/mol) and does not contribute meaningfully to macronutrient or micronutrient intake in any typical dosage form. As a lipophilic compound, it is dissolved in oil-based preparations or encapsulated in lipid carriers to enhance absorption; co-administration with dietary fat has been shown to increase oral bioavailability. Cannabis plant material contains additional phytochemicals including over 100 minor cannabinoids (CBD, CBN, CBG, CBC), more than 200 terpenes (myrcene, limonene, linalool, beta-caryophyllene), and flavonoids (cannflavins A and B) that may contribute to entourage effects modulating THC activity. The precursor THCA in raw cannabis is non-psychoactive and converts to THC upon decarboxylation (heating to approximately 110–120°C); THCA itself shows emerging anti-inflammatory activity in preclinical models.

Preparation & Dosage

- **Oral Capsule (Dronabinol/Marinol)**: FDA-approved synthetic THC; 2.5–10 mg orally 2–4 times daily for CINV; 2.5 mg twice daily for anorexia; bioavailability approximately 6% due to extensive first-pass metabolism.
- **Oromucosal Spray (Nabiximols/Sativex)**: Standardized THC:CBD spray delivering 2.7 mg THC and 2.5 mg CBD per actuation; typical titration up to 12 sprays/day for MS spasticity; bypasses some first-pass metabolism.
- **Inhalation (Smoked or Vaporized Cannabis)**: Bioavailability 10–30%; peak plasma concentrations within 3–10 minutes; dose highly variable depending on cultivar THC content (0.3%–30% THC by dry weight); not recommended for clinical standardization.
- **Rectal Suppository (THC Hemisuccinate)**: Bioavailability approximately 13.5%, roughly twofold higher than oral; doses of 2.5–5 mg have produced peak plasma concentrations of 1.1–4.1 ng/mL over 2–8 hours; used where oral route is impractical.
- **Sublingual Tincture/Oil**: THC concentrations in commercial oils range from 0 to 4.6% (v/v); onset 15–45 minutes; absorption partially bypasses first-pass metabolism; standardization varies widely by product.
- **Standardization Note**: Clinical-grade products are standardized to defined THC content (e.g., nabiximols to 27 mg/mL THC); consumer cannabis products lack equivalent standardization, making dose replication difficult.
- **Timing**: For CINV, dronabinol is typically administered 1–3 hours before chemotherapy; for chronic pain, twice-daily dosing maintains more consistent plasma levels given the 22-hour terminal half-life.

Synergy & Pairings

THC demonstrates significant pharmacological synergy with CBD (cannabidiol), which attenuates THC-induced anxiety, tachycardia, and psychotic symptoms by acting as a negative allosteric modulator at CB1 receptors while simultaneously contributing independent anti-inflammatory and analgesic effects—this combination is formalized in the nabiximols (Sativex) pharmaceutical product. Beta-caryophyllene, a sesquiterpene found in cannabis and other plants (black pepper, cloves), acts as a selective CB2 receptor agonist and may enhance the anti-inflammatory component of THC's therapeutic profile without additive psychoactivity, forming part of the proposed 'entourage effect' of whole-plant preparations. Co-administration of THC with medium-chain triglyceride (MCT) oil or other dietary fats substantially increases oral bioavailability by enhancing lymphatic absorption and reducing first-pass metabolism, making fat-containing formulations clinically preferable for oral cannabinoid delivery.

Safety & Interactions

At typical therapeutic doses, THC produces dose-dependent adverse effects including tachycardia, dry mouth, dizziness, impaired short-term memory, psychomotor impairment, and anxiety or dysphoria—particularly at higher doses or in naive users; acute psychosis is a rare but documented adverse event, especially in individuals with personal or family history of psychotic disorders. THC is a CYP3A4 and CYP2C9 substrate and inhibitor, creating clinically significant drug interactions with warfarin (increased anticoagulant effect, documented case reports of elevated INR), CNS depressants (additive sedation), and immunosuppressants such as tacrolimus and cyclosporine (altered plasma levels); concurrent use with sympathomimetics may exacerbate tachycardia. THC is contraindicated in individuals with a personal or first-degree family history of schizophrenia or other psychotic disorders, in those with severe hepatic impairment, and is classified as pregnancy Category C (dronabinol) due to evidence of fetal harm in animal studies and association with low birth weight and preterm birth in human observational data; it passes into breast milk and is contraindicated during lactation. Chronic high-dose use is associated with cannabis use disorder in approximately 9% of users (rising to ~17% for daily users), cannabinoid hyperemesis syndrome, and potential long-term cognitive effects particularly with adolescent-onset use; no established lethal dose has been documented in humans.